Financial Performance and Subsidiaries Revenue
EXPANDING ROW PRESENCE
NZ
CANADA
Strong portfolio with 30+ products including Oncology, anti-viral, cardiovascular and CNS therapies
Amongst top 10 generic companies by sales revenue in Canada
25 approvals in place
Highest market share of Nat-Lenalidomide in this molecule
Launched Nat-Pomalidomide, Nat-Apixaban, Nat-Teriflunomide in the market
NATCO
3,752
BRAZIL
Launched Apixaban in Brazil, amongst the first to launch, through own sales and out-licensing
Launched Azacitidine in Brazil through generic and brand, second generic in the market
Launched Gefitinib- first to launch and the only generic
Launched Vildagliptin, only generic and first-to-launch
Continue to be the single source for Everolimus for the fourth consecutive year
Strong market share for Oseltamivir
SUBSIDIARIES REVENUE ( IN MILLION)
4,011
Launched first generic Azacitidine in the market
PHILIPPINES
Gaining market share in branded generics in oncology by making available basket of products at attainable prices
Increasing reach in the country by selling products in additional provinces
1,086
1,085
1,814
…....
946
FY 2018
FY 2019
FY 2020
FY 2022
FY 2023
FY 2021*
Natco has 8 subsidiaries including two step-down subsidiaries
ASIA-PACIFIC
Participated and won large tender in Hong Kong market for Oseltamivir capsules
Launched Oseltamivir capsules in China market- Natco's first product launch in the territory
Won large tenders for Imatinib tablets & Erlotinib tablets in Thailand market
Launched first generic Apixaban in Myanmar, Thailand & Philippines
Acquired significant market share for Tenofovir Alafenamide Fumarate in Thailand, Indonesia & Vietnam markets
*Includes one-time licensing fee
8View entire presentation